GANX
Gain Therapeutics, Inc.3.8600
-0.0900-2.28%
Dec 16, 4:00:01 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
148.46MP/E (TTM)
-Basic EPS (TTM)
-0.61Dividend Yield
0%Recent Filings
8-K
8-K
KOL event on GT-02287 data
Gain Therapeutics hosted a virtual KOL event on October 14, 2025, spotlighting biomarkers, clinical endpoints, and disease modification potential for GT-02287 in Parkinson's disease. Experts Karl Kieburtz and Kenneth Marek discussed emerging Phase 1b data, emphasizing GBA1 mutations' role in faster disease progression and the drug's mechanism to restore GCase activity, reducing ER stress and alpha-synuclein aggregation. The open-label trial assesses safety, PK, and PD biomarkers like GCase activity in CSF over 90 days, with extension to nine months. Forward-looking statements highlight risks in clinical development.
8-K
Positive GT-02287 Phase 1b data
Gain Therapeutics unveiled preliminary Phase 1b data for GT-02287 in Parkinson's patients on October 6, 2025, showing the drug safe and well-tolerated after 90 days with no serious adverse events. Transient liver enzyme elevations normalized despite dosing, while mean UPDRS Part II and III scores improved, hinting at disease-slowing potential aligned with preclinical models. Data monitoring and Australian regulators greenlit a 12-month extension. Early signals boost the pipeline.
8-K
Phase 1b enrollment completed early
Gain Therapeutics hit full enrollment in its Phase 1b study of GT-02287 for Parkinson's disease ahead of schedule in Q2 2025, with 16 patients dosed and cap at 20. This milestone sets up key data on functional changes and biomarkers by Q4 2025, fueling Phase 2 design. Cash burn eased to $0.19 per share loss, bolstered by $7.1 million from a July public offering that extends runway past study end. Enrollment surged fast.
10-Q
Q2 FY2025 results
Gain Therapeutics narrowed its Q2 operating loss to $5.1 million, down 38% year-over-year from $8.2 million, as research and development expenses dropped 38% to $2.8 million amid grant offsets and pipeline tweaks, while general and administrative costs fell 38% to $2.3 million on lower stock-based comp. For the half-year, the net loss improved 15% to $10.3 million, or $0.35 per diluted share on 29.5 million weighted shares, with operating cash burn easing to $8.9 million versus $9.3 million last year. Cash stood at $6.7 million at quarter-end, bolstered by $4.9 million from ATM sales, but a July public offering added $7.1 million net to stretch into early 2026. No free cash flow or non-GAAP metrics disclosed in the 10-Q. Yet funding remains tight.
ADXN
Addex Therapeutics Ltd
7.56+0.55
ANNX
Annexon, Inc.
4.80-0.11
APLT
Applied Therapeutics, Inc.
0.12+0.00
ATHE
Alterity Therapeutics Limited
3.07+0.06
CGTX
Cognition Therapeutics, Inc.
1.52-0.08
DSGN
Design Therapeutics, Inc.
9.62+0.50
GLTO
Galecto, Inc.
30.00-1.60
GRTX
Galera Therapeutics, Inc.
0.02+0.00
IGC
IGC Pharma, Inc.
0.34+0.00
IKT
Inhibikase Therapeutics, Inc.
1.60-0.02